

## Greater Manchester Pathway Board Colorectal Cancer Surveillance Guidelines 2019

Groups	Time (months)											
	3	6	9	12	18	24	30	36	42	48	54	60
<b>1. Low risk</b> (endoscopically removed T1 polyp cancers)	Endoscopic visualisation of scar <sup>a</sup>	CEA		CEA CT TAP Colon*	CEA	CEA CT TAP	CEA	CEA		CEA Colon		CEA
<b>2. Intermediate</b> (Stage 1-3, Dukes A-C) tumours with curative resections **		CEA		CEA CT TAP Colon*	CEA	CEA CT TAP	CEA	CEA CT TAP		CEA Colon		CEA
<b>3. High risk</b> (Stage 4 disease) at presentation with primary & metastatic sites resected (liver, lung, peritoneum)		CEA CT TAP		CEA CT TAP Colon*	CEA CT TAP	CEA CT TAP	CEA	CEA CT TAP		CEA CT TAP Colon		CEA CT TAP
<b>4. 'Watch and Wait'</b> for Clinical complete response after chemoradiotherapy for rectal cancer (recruit to OnCoRe)	MRI F Sig	MRI F Sig CT TAP	MRI F Sig	MRI Colon* CT TAP	MRI F Sig CT TAP	MRI F Sig CT TAP	MRI F Sig	MRI F Sig CT TAP		F Sig CT TAP Colon		CT TAP

<sup>a</sup> Frequency of further investigation of scar depends on findings at the 3-month flexi sig or colonoscopy

\* Patients will have year 1 and 4 colonoscopy as per 2019 BSG guidelines

\*\* High risk patients in this group may have an additional scan at 60 months if clinically indicated